# Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Source: https://onco.cc/trials/nct05676931/  
OnCo record `nct05676931` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Domvanalimab, Quemliclustat, Zimberelimab in non-small-cell lung cancer and small-cell lung cancer, run by Gilead Sciences, active and no longer recruiting.

## Summary

Study With Various Immunotherapy Treatments in Participants With Lung Cancer is a phase 2 interventional study registered as NCT05676931 by Gilead Sciences, with 400 participants planned, started 2023-02-21 and due to reach its primary completion in 2027-12. Interventions recorded: Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet. Conditions listed: Advanced Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05676931
- Phase: 2
- Setting: A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer
- Sponsor: Gilead Sciences
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT05676931: https://clinicaltrials.gov/study/NCT05676931

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Domvanalimab](https://onco.cc/drugs/domvanalimab/), [Quemliclustat](https://onco.cc/drugs/quemliclustat/), [Zimberelimab](https://onco.cc/drugs/zimberelimab/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct05676931.json